University of Maryland, MedImmune Form Partnership to Advance Biomedical Science
MedImmune, the global biologics research and development arm of pharmaceutical giant AstraZeneca, and the University of Maryland, Baltimore (UMB) have entered into a five-year, $6 million collaboration to drive novel bioscience research in Maryland.